Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Dawn Swan, Michael E. O'Dwyer, Mary Cahill, Janusz Krawczyk, Vitaliy Mykytiv, John Quinn, Robert Henderson, Cian McEllistrim, Andres Hernando, Imelda Parker, Marc Nolan, Elizabeth Lenihan, Eva Szegezdi, Serika D Naicker, Kevin Lynch, Alessandro Natoni, Aideen Ryan, Philip Murphy

Blood (2021) 138 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2021-145530

Published: 2021

Journal Articles

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

John Daly, MSc, Subhashis Sarkar, PhD, Alessandro Natoni, PhD, Robert Henderson, MB BCh, Dawn Swan, Mattias Carlsten, MD PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 138.

https://doi.org/10.1182/blood-2019-126613

Published: 2019

Journal Articles

Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killer Cell-Mediated Cytotoxicity

Robert Henderson, MB BCh, Lucy Kirkham-McCarthy, MSc, Dawn Swan, BM BCh, Michael E O'Dwyer, MD, Alessandro Natoni, PhD

Blood (2018) 132 (Supplement 1): 4453.

https://doi.org/10.1182/blood-2018-99-116747

Published: 2018

Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2018-99-112375

Published: 2018

Journal Articles

CD38 low Natural Killer Cells Transiently Expressing CD16 F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide

Subhashis Sarkar, PhD, Sachin Chauhan, MSc, Arwen Stikvoort, PhD, Alessandro Natoni, PhD, John Daly, MSc, Robert Henderson, MB BCh, Tuna Mutis, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3199.

https://doi.org/10.1182/blood-2018-99-118926

Published: 2018

Journal Articles

Inhibition of Sialylation Impairs Adhesion on Madcam-1 and E-Selectin and Sensitize Multiple Myeloma Cells to Bortezomib in a Xenograft Mouse Model

Alessandro Natoni, PhD, Mariah Farrell, BS, Heather Fairfield, MS, Lucy Kirkham-McCarthy, MSc, Matt Macauley, PhD, Michaela Reagan, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2018-99-118361

Published: 2018

Journal Articles

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP

Serika Naicker, BSc, PhD, Athina Rigalou, BSc MSc, Cian McEllistrim, MB, BCh, BAO, Alessandro Natoni, PhD, Christopher Chiu, Kate Sasser, PhD, Aideen Ryan, BSc,PhD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 121.

https://doi.org/10.1182/blood.V130.Suppl_1.121.121

Published: 2017

Journal Articles

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

John Daly, MSc, Tony Duggan, BSc, Jinsong Hu, PhD, Alessandro Natoni, PhD, Subhashis Sarkar, PhD, Lucy Kirkham-McCarthy, MSc, Cian McEllistrim, MD, Janusz Krawczyk, MD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 1799.

https://doi.org/10.1182/blood.V130.Suppl_1.1799.1799

Published: 2017

Journal Articles

A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13)

Caoilfhionn Connolly, MB BCh BAO, Alokkumar Jha, MS, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2016) 128 (22): 4423.

https://doi.org/10.1182/blood.V128.22.4423.4423

Published: 2016

Journal Articles

Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP

Athina Rigalou, MSc., Aideen Ryan, PhD, Alessandro Natoni, PhD, Christopher Chiu, PhD, Kate Sasser, PhD, Michael E O'Dwyer, MD

Blood (2016) 128 (22): 2101.

https://doi.org/10.1182/blood.V128.22.2101.2101

Published: 2016

Journal Articles

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

Niamh Keane, MB BCh MRCPI, Mairead Reidy, PhD, Alessandro Natoni, PhD, Michael O'Dwyer, MD FRCPI, FRCPath

Blood (2015) 126 (23): 3007.

https://doi.org/10.1182/blood.V126.23.3007.3007

Published: 2015

Journal Articles

E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271

Alessandro Natoni, PhD, Theodore A.G. Smith, PhD, Niamh Keane, MB, MRCP, Silvia C. Locatelli-Hoops, PhD, Isabela Oliva, William E. Fogler, PhD, John L. Magnani, PhD, Michael O'Dwyer, MD

Blood (2015) 126 (23): 1805.

https://doi.org/10.1182/blood.V126.23.1805.1805

Published: 2015

Journal Articles

Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of Survival in a Murine Transplant Model

Alessandro Natoni, PhD, Michele Moschetta, MD, Siobhan Glavey, MD, Ping Wu, MBBS, MSc, Gareth J. Morgan, MD PhD, Lokesh Joshi, PhD, John L. Magnani, PhD, Irene M. Ghobrial, MD, Michael E O'Dwyer, MD FRCPI, FRCPath

Blood (2014) 124 (21): 4718.

https://doi.org/10.1182/blood.V124.21.4718.4718

Published: 2014

Journal Articles

The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma

Siobhan V. Glavey, Salomon Manier, Alessandro Natoni, Antonio Sacco, Michele Moschetta, Michaela R. Reagan, Laura S. Murillo, Ilyas Sahin, Ping Wu, Yuji Mishima, Yu Zhang, Wenjing Zhang, Yong Zhang, Gareth Morgan, Lokesh Joshi, Aldo M. Roccaro, Irene M. Ghobrial, Michael E. O’Dwyer

Blood (2014) 124 (11): 1765–1776.

https://doi.org/10.1182/blood-2014-03-560862

Published: 2014

Includes: Supplemental data

Journal Articles

Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo

Siobhan Glavey, MD, Salomon Manier, MD, Antonio Sacco, BS, Michaela R Reagan, PhD, Yuji Mishima, PhD, Yong Zhang, PhD, Ilyas Sahin, MD, Yu Zhang, MD, Wenjing Zhang, MD, Laura S Murillo, PhD, Catherine Loughrey, MSc, Alessandro Natoni, PhD, Katarzyna Kazlowska, Lokesh Joshi, PhD, Aldo M Roccaro, MD, PhD, Irene M. Ghobrial, MD, Michael E O'Dwyer, MD, FRCPI, FRCPath

Blood (2013) 122 (21): 275.

https://doi.org/10.1182/blood.V122.21.275.275

Published: 2013

Journal Articles

PHA767491, a Dual Cdc7/CDK9 Inhibitor, with Potential to Target Both Proliferation and Survival in CLL.

Alessandro Natoni, PhD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Alessia Montagnoli, PhD, Grace Callagy, MB, PhD, MRCPI, FRCPath, Afshin Samali, PhD, Corrado Santocanale, PhD, Michael C O'Dwyer, MD, FRCPI, FRCPath

Blood (2009) 114 (22): 2366.

https://doi.org/10.1182/blood.V114.22.2366.2366

Published: 2009

NARROW

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killer Cell-Mediated Cytotoxicity

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

CD38 low Natural Killer Cells Transiently Expressing CD16 F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide

Inhibition of Sialylation Impairs Adhesion on Madcam-1 and E-Selectin and Sensitize Multiple Myeloma Cells to Bortezomib in a Xenograft Mouse Model

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13)

Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271

Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of Survival in a Murine Transplant Model

The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma

Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo

PHA767491, a Dual Cdc7/CDK9 Inhibitor, with Potential to Target Both Proliferation and Survival in CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only